Grant: Alliance Grants
McMaster University
$290,329.00
Advancing automation in integrated continuous biomanufacturing processes
FY 2024-25
Summary
Recent advances in the development of biotherapeutics, often referred to as "living drugs", have the potential to treat and/or cure patients afflicted with various diseases that were once thought to be unbeatable. However, the traditional technologies and processes that are employed to produce biotherapeutics result in dramatically high treatment costs for patients. The transition from batch to continuous biomanufacturing (analogous to what the field of engineering accomplished in the chemical and petroleum industries many years ago) is now widely seen as the most impactful way to dramatically increase the affordability of biotherapeutics. However, the development of an entirely continuous biomanufacturing process first requires a number of scientific/technological breakthroughs. In this context, a strategic and synergistic partnership between McMaster University and Sartorius Canada was created to address the major knowledge gaps related to automation, modelling, and control of integrated, continuous biomanufacturing processes. As part of this collaboration, Canada's first automation-focused biomanufacturing research facility will be established - this purpose built, modular research facility will be outfitted with many pieces of state-of-the-art biomanufacturing equipment and thus serve as the core of a 'biomanufacturing ecosystem' where a cadre of graduate and undergraduate students work alongside researchers from Sartorius, other research institutions, and other Canadian-based companies in an integrated, energetic, learning and research environment. While this project will develop technologies in the context of monoclonal antibody and adenovirus production, the techniques developed in the proposal will be widely applicable to other biotherapeutics. Overall, this work will vault Canada's position to the forefront of the global push towards making fully continuous biomanufacturing the new standard for biomanufacturing facilities which will result in current and future biotherapeutics that are much more affordable and available to all Canadians.
Program
Alliance Grants
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
597447-2024
Name nom
Latulippe, David DR
Department département
Chemical Engineering
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2024
Award amount
290329
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
1802
Research subject group en
Chemical engineering
Research subject group fr
Génie chimique
Research subject en
Biochemical engineering
Research subject fr
Génie biochimique
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Advancing automation in integrated continuous biomanufacturing processes
Keywords
advanced automation systems; biomanufacturing; continuous chromatography; data driven optimal control; dynamic economic optimization; membrane-based perfusion processes; model scale-up & intensification; monoclonal antibodies; process analytical technology tools; therapeutic viruses
Application summary
Recent advances in the development of biotherapeutics, often referred to as "living drugs", have the potential to treat and/or cure patients afflicted with various diseases that were once thought to be unbeatable. However, the traditional technologies and processes that are employed to produce biotherapeutics result in dramatically high treatment costs for patients. The transition from batch to continuous biomanufacturing (analogous to what the field of engineering accomplished in the chemical and petroleum industries many years ago) is now widely seen as the most impactful way to dramatically increase the affordability of biotherapeutics. However, the development of an entirely continuous biomanufacturing process first requires a number of scientific/technological breakthroughs. In this context, a strategic and synergistic partnership between McMaster University and Sartorius Canada was created to address the major knowledge gaps related to automation, modelling, and control of integrated, continuous biomanufacturing processes. As part of this collaboration, Canada's first automation-focused biomanufacturing research facility will be established - this purpose built, modular research facility will be outfitted with many pieces of state-of-the-art biomanufacturing equipment and thus serve as the core of a 'biomanufacturing ecosystem' where a cadre of graduate and undergraduate students work alongside researchers from Sartorius, other research institutions, and other Canadian-based companies in an integrated, energetic, learning and research environment. While this project will develop technologies in the context of monoclonal antibody and adenovirus production, the techniques developed in the proposal will be widely applicable to other biotherapeutics. Overall, this work will vault Canada's position to the forefront of the global push towards making fully continuous biomanufacturing the new standard for biomanufacturing facilities which will result in current and future biotherapeutics that are much more affordable and available to all Canadians.